U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Vive Minerals LLC - Online Advisory Letter
  1. Inspections, Compliance, Enforcement, and Criminal Investigations

Vive Minerals LLC - Online Advisory Letter

Black HHS-Blue FDA Logo

 

 

Food and Drug Administration
Silver Spring, MD 20993-0002

 

Online Advisory Letter Reference #676831

 

April 26, 2024                  

Jeanne Grant
Vive Minerals, LLC
321 Marina Village Cove
Austin, TX 78734
jeannegrant@live.com

RE: Vive mineral supplement

Dear Ms. Grant,

This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https://viveminerals.com in April 2024 and has found that you take orders there for Vive mineral supplement. Various claims and statements made on your website and/or in other labeling establish that this product is a drug as defined in 21 U.S.C. § 321(g)(1)(B) because it is intended for the treatment, cure, mitigation, or prevention of disease. For example, your website recommends or suggests the use of Vive mineral supplement to treat or prevent anorexia, depression, and seizures. As explained further below, the introduction of this product into interstate commerce for such uses violates the Federal Food, Drug, and Cosmetic Act.  

This product is also a new drug as defined under 21 U.S.C. § 321(p) because it is not generally recognized as safe and effective for the uses recommended or suggested in its labeling. Before a new drug may be marketed or otherwise introduced into interstate commerce, it must be approved by FDA on the basis of scientific data demonstrating that the drug is safe and effective under the conditions of use in its labeling. See 21 U.S.C. §§ 355(a) and 331(d). Your drug product does not have an FDA-approved application as required by 21 U.S.C. § 355.  
 
We advise you to review all materials through which you communicate to consumers the intended uses of your product, and to either submit a new drug application (NDA) for a product intended for use in treating, curing, mitigating, diagnosing, or preventing a disease or, alternatively, remove all statements indicating that your product is intended for such uses. This would include reviewing your websites, product labels, catalogs, brochures, flyers, package inserts, audio and video, e-commerce and social media accounts you operate (e.g., Amazon, eBay, Facebook and Twitter accounts), as well as any other promotional materials, and removing product claims, consumer testimonials, metatags, and anything else that states or implies that your product is useful in treating, curing, mitigating, diagnosing, or preventing diseases.  

For more information on the kinds of claims that establish that a product is intended for use as a drug, please see 21 CFR 101.93(f)-(g) and https://www.fda.gov/food/food-labeling-nutrition/label-claims-conventional-foods-and-dietary-supplements.

Within 30 calendar days of the date of this letter, please correct the violations described in this letter and notify FDA, via electronic mail at FDAadvisory@fda.hhs.gov, that the violations have been corrected.  Include the Online Advisory Letter Reference number (located in the upper right portion of this letter) in all your communications to FDA regarding this matter.  

After 30 days from the date of this letter, if your website or other labeling continue to demonstrate that your product is intended to treat, cure, mitigate, or prevent diseases, the name of your firm and this letter will be posted on the FDA webpage for products illegally marketed for serious diseases.  

This letter is not intended to be an all-inclusive review of your website or a list of all violations of law that exist in connection with your product, your website and other product labeling, or at your facilities. FDA expects you to take the necessary steps to ensure that your product complies with the laws and regulations enforced by FDA.

Sincerely,

 

Health Fraud Branch
Office of Regulatory Affairs
U.S. Food and Drug Administration
 

 

 
Back to Top